

Freya J I Fowkes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/398667/publications.pdf>

Version: 2024-02-01

110
papers

6,096
citations

94433

37
h-index

82547

72
g-index

117
all docs

117
docs citations

117
times ranked

6811
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of naturally acquired antimalarial antibodies in subclinical <i>Plasmodium</i> spp. infection. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1097-1105.	3.3	4
2	Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women. <i>Malaria Journal</i> , 2022, 21, 75.	2.3	7
3	Can malaria parasites be spontaneously cleared?. <i>Trends in Parasitology</i> , 2022, 38, 356-364.	3.3	8
4	Perspectives of health and community stakeholders on community-delivered models of malaria elimination in Lao People's Democratic Republic: A qualitative study. <i>PLoS ONE</i> , 2022, 17, e0264399.	2.5	0
5	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 804470.	3.9	1
6	The Global Epidemiological Transition in Cardiovascular Diseases: Unrecognised Impact of Endemic Infections on Peripheral Artery Disease. <i>Journal of Epidemiology and Global Health</i> , 2022, 12, 219-223.	2.9	4
7	Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial. <i>Journal of Infectious Diseases</i> , 2021, 224, 1128-1138.	4.0	38
8	Community demand for comprehensive primary health care from malaria volunteers in South-East Myanmar: a qualitative study. <i>Malaria Journal</i> , 2021, 20, 19.	2.3	6
9	Optimizing Myanmar's community-delivered malaria volunteer model: a qualitative study of stakeholders' perspectives. <i>Malaria Journal</i> , 2021, 20, 79.	2.3	6
10	A mobile phone application for malaria case-based reporting to advance malaria surveillance in Myanmar: a mixed methods evaluation. <i>Malaria Journal</i> , 2021, 20, 167.	2.3	9
11	Community-based molecular and serological surveillance of subclinical malaria in Myanmar. <i>BMC Medicine</i> , 2021, 19, 121.	5.5	6
12	Development and Validation of an <i>In Silico</i> Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	1
13	High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women. <i>Frontiers in Immunology</i> , 2021, 12, 644563.	4.8	3
14	Reduced risk of placental parasitemia associated with complement fixation on <i>Plasmodium falciparum</i> by antibodies among pregnant women. <i>BMC Medicine</i> , 2021, 19, 201.	5.5	10
15	Evaluation of the effectiveness and cost effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) model in Myanmar: protocol for an open stepped-wedge cluster-randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e050400.	1.9	0
16	Sustainability of a mobile phone application-based data reporting system in Myanmar's malaria elimination program: a qualitative study. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 285.	3.0	2
17	<i>Anopheles</i> salivary antigens as serological biomarkers of vector exposure and malaria transmission: A systematic review with multilevel modelling. <i>ELife</i> , 2021, 10, .	6.0	7
18	Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks against <i>Plasmodium</i> spp. infection in Myanmar: A stepped-wedge cluster randomised trial. <i>PLoS Medicine</i> , 2020, 17, e1003177.	8.4	16

#	ARTICLE	IF	CITATIONS
19	Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review. <i>BMC Medicine</i> , 2020, 18, 14.	5.5	48
20	The invisible burden of malaria-attributable stillbirths. <i>Lancet</i> , The, 2020, 395, 268.	13.7	5
21	Understanding the interactions between iron supplementation, infectious disease and adverse birth outcomes is essential to guide public health recommendations. <i>BMC Medicine</i> , 2019, 17, 153.	5.5	5
22	The impact of community-delivered models of malaria control and elimination: a systematic review. <i>Malaria Journal</i> , 2019, 18, 269.	2.3	28
23	Induction and Kinetics of Complement-Fixing Antibodies Against <i>Plasmodium vivax</i> Merozoite Surface Protein 31± and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. <i>Journal of Infectious Diseases</i> , 2019, 220, 1950-1961.	4.0	15
24	Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. <i>The Lancet Global Health</i> , 2019, 7, e1020-e1030.	6.3	662
25	Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria. <i>Trends in Parasitology</i> , 2019, 35, 529-543.	3.3	40
26	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. <i>Journal of Infectious Diseases</i> , 2019, 220, 1178-1187.	4.0	21
27	Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure. <i>BMC Medicine</i> , 2019, 17, 45.	5.5	65
28	Targets of complement-fixing antibodies in protective immunity against malaria in children. <i>Nature Communications</i> , 2019, 10, 610.	12.8	76
29	Antibody Targets on the Surface of <i>Plasmodium falciparum</i> Infected Erythrocytes That Are Associated With Immunity to Severe Malaria in Young Children. <i>Journal of Infectious Diseases</i> , 2019, 219, 819-828.	4.0	28
30	Effectiveness of repellent delivered through village health volunteers on malaria incidence in villages in South-East Myanmar: a stepped-wedge cluster-randomised controlled trial protocol. <i>BMC Infectious Diseases</i> , 2018, 18, 663.	2.9	10
31	Iron deficiency during pregnancy is associated with a reduced risk of adverse birth outcomes in a malaria-endemic area in a longitudinal cohort study. <i>BMC Medicine</i> , 2018, 16, 156.	5.5	22
32	In Silico Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	4
33	Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating <i>Plasmodium falciparum</i> Malaria Patients Using Mathematical Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	43
34	Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model. <i>Malaria Journal</i> , 2018, 17, 279.	2.3	26
35	Human antibodies activate complement against <i>Plasmodium falciparum</i> sporozoites, and are associated with protection against malaria in children. <i>BMC Medicine</i> , 2018, 16, 61.	5.5	79
36	Anopheles Salivary Biomarker as a Proxy for Estimating <i>Plasmodium falciparum</i> Malaria Exposure on the Thailand-Myanmar Border. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 350-356.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight. <i>BMC Medicine</i> , 2017, 15, 1.	5.5	242
38	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3515-3520.	7.1	78
39	Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2017, 5, e1101-e1112.	6.3	102
40	A Dynamic Stress Model Explains the Delayed Drug Effect in Artemisinin Treatment of <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	9
41	Patterns of protective associations differ for antibodies to <i>P. falciparum</i> -infected erythrocytes and merozoites in immunity against malaria in children. <i>European Journal of Immunology</i> , 2017, 47, 2124-2136.	2.9	21
42	Declining Malaria Transmission Differentially Impacts the Maintenance of Humoral Immunity to <i>Plasmodium falciparum</i> in Children. <i>Journal of Infectious Diseases</i> , 2017, 216, 887-898.	4.0	31
43	Mediation of the effect of malaria in pregnancy on stillbirth and neonatal death in an area of low transmission: observational data analysis. <i>BMC Medicine</i> , 2017, 15, 98.	5.5	43
44	Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission. <i>BMC Medicine</i> , 2017, 15, 117.	5.5	62
45	Immunity as a predictor of anti-malarial treatment failure: a systematic review. <i>Malaria Journal</i> , 2017, 16, 158.	2.3	13
46	Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance. <i>Journal of Leukocyte Biology</i> , 2017, 101, 913-925.	3.3	41
47	Peripheral artery disease: epidemiology and global perspectives. <i>Nature Reviews Cardiology</i> , 2017, 14, 156-170.	13.7	470
48	Recent insights into humoral immunity targeting <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria. <i>International Journal for Parasitology</i> , 2017, 47, 99-104.	3.1	14
49	Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 723-731.	4.0	15
50	<i>P. falciparum</i> infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission. <i>PLoS ONE</i> , 2017, 12, e0186577.	2.5	17
51	Antibody Responses to <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> and Prospective Risk of <i>Plasmodium</i> spp. Infection Postpartum. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 1197-1204.	1.4	1
52	Association between malaria immunity and pregnancy outcomes among Malawian pregnant women receiving nutrient supplementation. <i>Malaria Journal</i> , 2016, 15, 547.	2.3	8
53	A malaria vaccine in children with HIV. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1087-1089.	9.1	0
54	Water, Sanitation, and Hygiene Facilities and Hygiene Practices Associated with Diarrhea and Vomiting in Monastic Schools, Myanmar. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 278-287.	1.4	13

#	ARTICLE	IF	CITATIONS
55	Immunity to malaria in an era of declining malaria transmission. <i>Parasitology</i> , 2016, 143, 139-153.	1.5	66
56	The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from <i>Plasmodium falciparum</i> malaria. <i>Scientific Reports</i> , 2016, 6, 33094.	3.3	59
57	A single point in protein trafficking by <i>Plasmodium falciparum</i> determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 4141-4158.	5.4	20
58	Antibody responses to <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> blood-stage and sporozoite antigens in the postpartum period. <i>Scientific Reports</i> , 2016, 6, 32159.	3.3	6
59	Maternal-foetal transfer of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> antibodies in a low transmission setting. <i>Scientific Reports</i> , 2016, 6, 20859.	3.3	13
60	Achieving development goals for HIV, tuberculosis and malaria in sub-Saharan Africa through integrated antenatal care: barriers and challenges. <i>BMC Medicine</i> , 2016, 14, 202.	5.5	23
61	Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria. <i>Malaria Journal</i> , 2016, 15, 258.	2.3	23
62	Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 576-583.	9.1	67
63	Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. <i>FEMS Microbiology Reviews</i> , 2016, 40, 343-372.	8.6	275
64	Presenting parasitological data: the good, the bad and the error bar. <i>Parasitology</i> , 2015, 142, 1351-1363.	1.5	0
65	The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial. <i>Malaria Journal</i> , 2015, 14, 193.	2.3	15
66	<i>Plasmodium vivax</i> Malaria. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 529-531.	2.0	14
67	Acquisition of Antibodies against <i>Plasmodium falciparum</i> Merozoites and Malaria Immunity in Young Children and the Influence of Age, Force of Infection, and Magnitude of Response. <i>Infection and Immunity</i> , 2015, 83, 646-660.	2.2	121
68	Trying to remember: immunological B cell memory to malaria. <i>Trends in Parasitology</i> , 2015, 31, 89-94.	3.3	38
69	Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during <i>Plasmodium falciparum</i> Invasion of Erythrocytes. <i>PLoS Pathogens</i> , 2015, 11, e1004670.	4.7	246
70	Maximizing antimalarial efficacy and the importance of dosing strategies. <i>BMC Medicine</i> , 2015, 13, 110.	5.5	8
71	Malaria eradication and elimination: views on how to translate a vision into reality. <i>BMC Medicine</i> , 2015, 13, 167.	5.5	101
72	Estimating Gestational Age in Late Presenters to Antenatal Care in a Resource-Limited Setting on the Thai-Myanmar Border. <i>PLoS ONE</i> , 2015, 10, e0131025.	2.5	36

#	ARTICLE	IF	CITATIONS
73	Research priorities for the development and implementation of serological tools for malaria surveillance. <i>F1000prime Reports</i> , 2014, 6, 100.	5.9	56
74	Use of Immunodampening To Overcome Diversity in the Malarial Vaccine Candidate Apical Membrane Antigen 1. <i>Infection and Immunity</i> , 2014, 82, 4707-4717.	2.2	10
75	Immunological markers of <i>Plasmodium vivax</i> exposure and immunity: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2014, 12, 150.	5.5	66
76	Surface antigens of <i>Plasmodium falciparum</i> -infected erythrocytes as immune targets and malaria vaccine candidates. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 3633-3657.	5.4	131
77	Antibody Boosting and Longevity Following Tetanus Immunization During Pregnancy. <i>Clinical Infectious Diseases</i> , 2013, 56, 749-750.	5.8	6
78	PfEMP1 as a target of human immunity and a vaccine candidate against malaria. <i>Expert Review of Vaccines</i> , 2013, 12, 105-108.	4.4	17
79	Reply to Eisenhut. <i>Journal of Infectious Diseases</i> , 2013, 208, 705-706.	4.0	0
80	Erythrocyte-Binding Antigens of <i>Plasmodium falciparum</i> Are Targets of Human Inhibitory Antibodies and Function To Evade Naturally Acquired Immunity. <i>Journal of Immunology</i> , 2013, 191, 785-794.	0.8	62
81	Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to <i>Plasmodium falciparum</i> Malaria for Vaccine and Biomarker Development. <i>Journal of Immunology</i> , 2013, 191, 795-809.	0.8	213
82	Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines. <i>BMC Medicine</i> , 2013, 11, 232.	5.5	13
83	Epistatic Interactions between Apolipoprotein E and Hemoglobin S Genes in Regulation of Malaria Parasitemia. <i>PLoS ONE</i> , 2013, 8, e76924.	2.5	15
84	New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women. <i>Journal of Infectious Diseases</i> , 2012, 206, 1612-1621.	4.0	85
85	Bacterial Vaginosis (BV) Candidate Bacteria: Associations with BV and Behavioural Practices in Sexually-Experienced and Inexperienced Women. <i>PLoS ONE</i> , 2012, 7, e30633.	2.5	69
86	The <i>Plasmodium falciparum</i> Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria. <i>PLoS ONE</i> , 2012, 7, e45253.	2.5	51
87	Individual Variation in Levels of Haptoglobin-Related Protein in Children from Gabon. <i>PLoS ONE</i> , 2012, 7, e49816.	2.5	7
88	Targets of antibodies against <i>Plasmodium falciparum</i> -infected erythrocytes in malaria immunity. <i>Journal of Clinical Investigation</i> , 2012, 122, 3227-3238.	8.2	187
89	A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720. <i>PLoS ONE</i> , 2011, 6, e24413.	2.5	88
90	Quantifying the Importance of MSP1-19 as a Target of Growth-Inhibitory and Protective Antibodies against <i>Plasmodium falciparum</i> in Humans. <i>PLoS ONE</i> , 2011, 6, e27705.	2.5	49

#	ARTICLE	IF	CITATIONS
91	Quantifying Malaria Dynamics Within the Host. <i>Science</i> , 2011, 333, 943-944.	12.6	1
92	The Stability and Complexity of Antibody Responses to the Major Surface Antigen of <i>Plasmodium falciparum</i> Are Associated with Age in a Malaria Endemic Area. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M111.008326.	3.8	78
93	Intermittent Preventive Treatment to Reduce the Burden of Malaria in Children: New Evidence on Integration and Delivery. <i>PLoS Medicine</i> , 2011, 8, e1000410.	8.4	5
94	Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against <i>Plasmodium falciparum</i> Malaria. <i>Journal of Immunology</i> , 2010, 185, 6157-6167.	0.8	84
95	Association between Naturally Acquired Antibodies to Erythrocyte-Binding Antigens of <i>Plasmodium falciparum</i> and Protection from Malaria and High-Density Parasitemia. <i>Clinical Infectious Diseases</i> , 2010, 51, e50-e60.	5.8	184
96	Antibodies to Chondroitin Sulfate A-Binding Infected Erythrocytes: Dynamics and Protection during Pregnancy in Women Receiving Intermittent Preventive Treatment. <i>Journal of Infectious Diseases</i> , 2010, 201, 1316-1325.	4.0	35
97	Evaluation of the Antigenic Diversity of Placenta-Binding <i>Plasmodium falciparum</i> Variants and the Antibody Repertoire among Pregnant Women. <i>Infection and Immunity</i> , 2010, 78, 1963-1978.	2.2	51
98	The Relationship between Anti-merozoite Antibodies and Incidence of <i>Plasmodium falciparum</i> Malaria: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2010, 7, e1000218.	8.4	306
99	The acute phase response in children with mild and severe malaria in Papua New Guinea. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2009, 103, 679-686.	1.8	25
100	Scottish smoke-free legislation and trends in smoking cessation. <i>Addiction</i> , 2008, 103, 1888-1895.	3.3	48
101	Host erythrocyte polymorphisms and exposure to <i>Plasmodium falciparum</i> in Papua New Guinea. <i>Malaria Journal</i> , 2008, 7, 1.	2.3	161
102	Increased Microerythrocyte Count in Homozygous $\beta^{\pm\pm}$ -Thalassaemia Contributes to Protection against Severe Malarial Anaemia. <i>PLoS Medicine</i> , 2008, 5, e56.	8.4	55
103	Bypass surgery for chronic lower limb ischaemia. , 2008, , CD002000.		60
104	Acquisition of Growth-Inhibitory Antibodies against Blood-Stage <i>Plasmodium falciparum</i> . <i>PLoS ONE</i> , 2008, 3, e3571.	2.5	88
105	LOW PREVALENCE OF AN ACUTE PHASE RESPONSE IN ASYMPTOMATIC CHILDREN FROM A MALARIA-ENDEMIC AREA OF PAPUA NEW GUINEA. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 76, 280-284.	1.4	35
106	ASSOCIATION OF HAPTOGLOBIN LEVELS WITH AGE, PARASITE DENSITY, AND HAPTOGLOBIN GENOTYPE IN A MALARIA-ENDEMIC AREA OF GABON. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 74, 26-30.	1.4	30
107	HAPTOGLOBIN LEVELS ARE ASSOCIATED WITH HAPTOGLOBIN GENOTYPE AND $\beta^{\pm\pm}$ -THALASSEMIA IN A MALARIA-ENDEMIC AREA. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 74, 965-971.	1.4	33
108	Association of haptoglobin levels with age, parasite density, and haptoglobin genotype in a malaria-endemic area of Gabon. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 74, 26-30.	1.4	19

#	ARTICLE	IF	CITATIONS
109	Haptoglobin levels are associated with haptoglobin genotype and alpha+ -Thalassemia in a malaria-endemic area. American Journal of Tropical Medicine and Hygiene, 2006, 74, 965-71.	1.4	22
110	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	4.0	1